Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Value Type description Interaction Map Rank Gene Network Comparison Type Filtered green red network_comparison
Results: HTML CSV LaTeX Showing element 1930 to 1979 of 3228 in total 
Value Type: Measured
Interaction Map: High confidence
Network Comparison Type: Divided
Filtered: 1

\def\wcA{0.16666666666667\textwidth}
\def\wcB{0.16666666666667\textwidth}
\def\wcC{0.16666666666667\textwidth}
\def\wcD{0.16666666666667\textwidth}
\def\wcE{0.16666666666667\textwidth}
\begin{longtable}{|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
orphan nuclear receptor nurr1 (immediate-early response protein not) (transcriptionally inducible nuclear receptor). [source:swissprot;acc:p43354]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1283\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6742.79\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6229.16\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08246\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
orphan nuclear receptor tr2. [source:swissprot;acc:p13056]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1317\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6599.06\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6105.69\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0808\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
osteoclast stimulating factor 1. [source:swissprot;acc:q92882]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2542\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4817.39\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4708.98\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02302\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
ovarian carcinoma immunoreactive antigen. [source:refseq;acc:nm\_017830]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1829\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5997\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5633.44\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06454\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
oxidation resistance 1. [source:refseq;acc:nm\_181354]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2138\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6173.7\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5859.1\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05369\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
oxysterols receptor lxr-alpha (liver x receptor alpha) (nuclear orphan receptor lxr-alpha). [source:swissprot;acc:q13133]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1695\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
6165.87\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
5767.69\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.06904\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
oxysterols receptor lxr-beta (liver x receptor beta) (nuclear orphan receptor lxr-beta) (ubiquitously-expressed nuclear receptor) (nuclear receptor ner). [source:swissprot;acc:p55055]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1690\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
p protein (melanocyte-specific transporter protein). [source:swissprot;acc:q04671]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1327\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6111.9\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5656.8\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08045\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
p10-binding protein. [source:refseq;acc:nm\_024491]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1236\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6067.49\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5594.18\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08461\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
p28 ing5. [source:refseq;acc:nm\_032329]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1930\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6141.48\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5784.06\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06179\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
p29ing4; candidate tumor suppressor p33 ing1 homolog. [source:refseq;acc:nm\_016162]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1460\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6130.26\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5696.65\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07612\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
p300/cbp-associated factor (ec 2.3.1.-) (p/caf) (histone acetylase pcaf). [source:swissprot;acc:q92831]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1943\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
7649.23\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7210.87\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06079\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
p47 protein isoform a. [source:refseq;acc:nm\_016143]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1467\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6932.39\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6444.4\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07572\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
p53-related protein kinase (ec 2.7.1.-) (nori-2). [source:swissprot;acc:q96s44]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1246\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5796.72\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5346.11\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08429\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
p66 alpha. [source:refseq;acc:nm\_017660]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
353\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
10911.1\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
12839\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.17669\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
paired box protein pax-6 (oculorhombin) (aniridia, type ii protein). [source:swissprot;acc:p26367]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2081\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6670.1\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6318.3\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05568\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pak1 interacting protein 1; pak1-interacting protein; pak/plc-interacting protein 1. [source:refseq;acc:nm\_017906]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3072\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pallidin; pallid (mouse) homolog, pallidin. [source:refseq;acc:nm\_012388]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
302\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
7073.65\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5894.75\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.19999\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
palmitoyl-protein thioesterase 1 precursor (ec 3.1.2.22) (palmitoyl- protein hydrolase 1). [source:swissprot;acc:p50897]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2717\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5583.64\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5603.24\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00351\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
palmitoyl-protein thioesterase 2 precursor (ec 3.1.2.22) (palmitoyl- protein hydrolase 2) (ppt-2) (g14). [source:swissprot;acc:q9umr5]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1477\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
3429.37\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3687.37\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07523\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pantothenate kinase 1 (ec 2.7.1.33) (pantothenic acid kinase 1) (hpank1) (hpank). [source:swissprot;acc:q8te04]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
116\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
28492\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
21185\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.34491\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
pantothenate kinase 2, mitochondrial precursor (ec 2.7.1.33) (pantothenic acid kinase 2) (hpank2). [source:swissprot;acc:q9bz23]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
117\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
pantothenate kinase 3 (ec 2.7.1.33) (pantothenic acid kinase 3) (hpank3). [source:swissprot;acc:q9h999]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
118\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pantothenate kinase 4 (ec 2.7.1.33) (pantothenic acid kinase 4) (hpank4). [source:swissprot;acc:q9nve7]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2883\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
parafibromin. [source:refseq;acc:nm\_024529]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
894\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4771.22\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4331.17\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.1016\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
paraspeckle protein 1. [source:refseq;acc:nm\_018282]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2029\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
9685.21\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
10241.3\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05742\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
parkinson disease (autosomal recessive, juvenile) 2, parkin isoform 1; parkin. [source:refseq;acc:nm\_004562]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
382\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5279.4\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4533.74\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.16447\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
partitioning defective-6 homolog gamma (par-6 gamma) (par6d). [source:swissprot;acc:q9byg4]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
662\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
7145.59\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6374.65\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.12094\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pas domain containing serine/threonine kinase; pas-serine/threonine kinase. [source:refseq;acc:nm\_015148]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1634\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
9251.16\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
9899.73\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07011\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
paxillin. [source:swissprot;acc:p49023]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
284\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6314.35\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5221.28\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.20935\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pbk1 protein. [source:sptrembl;acc:o76021]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
838\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4493.36\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4064.23\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.10559\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pc4 and sfrs1 interacting protein 2; pc4 and sfrs1 interacting protein 1; transcriptional coactivator p52/p75. [source:refseq;acc:nm\_033222]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
385\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5279.4\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4533.74\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.16447\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pdz/coiled-coil domain binding partner for the rho-family gtpase tc10; fused in glioblastoma; golgi associated pdz and coiled-coil motif containing protein; cftr-associated ligand. [source:refseq;acc:nm\_020399]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2456\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6166.89\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5978.83\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.03145\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pef protein with a long n-terminal hydrophobic domain (peflin). [source:refseq;acc:nm\_012392]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
426\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6853.15\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5942.49\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.15325\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
pepsin a precursor (ec 3.4.23.1). [source:swissprot;acc:p00790]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1178\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4776.19\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4392.63\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08732\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peptide chain release factor 1, mitochondrial precursor (mrf-1). [source:swissprot;acc:o75570]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
880\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5694.55\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5166.04\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.1023\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peptide deformylase, mitochondrial precursor (ec 3.5.1.88) (pdf) (polypeptide deformylase). [source:swissprot;acc:q9hbh1]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2884\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peptide methionine sulfoxide reductase (ec 1.8.4.6) (protein- methionine-s-oxide reductase) (peptide met(o) reductase). [source:swissprot;acc:q9uj68]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1106\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5986.63\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5489.99\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.09046\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peptidyl prolyl isomerase h; cyclophilin h. [source:refseq;acc:nm\_006347]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2706\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
9012.31\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8979.61\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00364\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peptidyl-prolyl cis-trans isomerase b precursor (ec 5.2.1.8) (ppiase) (rotamase) (cyclophilin b) (s-cyclophilin) (scylp) (cyp-s1). [source:swissprot;acc:p23284]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
961\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
10733.2\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
11773\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.09688\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peptidyl-prolyl cis-trans isomerase e (ec 5.2.1.8) (ppiase e) (rotamase e) (cyclophilin e) (cyclophilin 33). [source:swissprot;acc:q9unp9]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1504\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
9377.75\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
10075.5\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0744\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peptidyl-prolyl cis-trans isomerase nima-interacting 1 (ec 5.2.1.8) (rotamase pin1) (ppiase pin1). [source:swissprot;acc:q13526]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1446\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5510.45\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5117.85\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07671\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peptidylprolyl isomerase-like 4; cyclophilin-type peptidyl-prolyl cis-trans isomerase; ppiase; serologically defined breast cancer antigen ny-br-18. [source:refseq;acc:nm\_139126]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2073\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6423.12\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6083.39\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05585\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peregrin (bromodomain and phd finger-containing protein 1) (br140 protein). [source:swissprot;acc:p55201]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2820\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
pericentrin 1; frount; nucleoporin nup75. [source:refseq;acc:nm\_024844]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3015\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peripheral plasma membrane protein cask (ec 2.7.1.-) (hcask) (calcium/calmodulin-dependent serine protein kinase) (lin-2 homolog). [source:swissprot;acc:o14936]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1006\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6249.1\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5707.73\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.09485\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peroxiredoxin 4 (ec 1.11.1.-) (prx-iv) (thioredoxin peroxidase ao372) (thioredoxin-dependent peroxide reductase a0372) (antioxidant enzyme aoe372) (aoe37-2). [source:swissprot;acc:q13162]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1302\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6862.94\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6343.26\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08193\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peroxiredoxin 5, mitochondrial precursor (prx-v) (peroxisomal antioxidant enzyme) (plp) (thioredoxin peroxidase pmp20) (antioxidant enzyme b166) (aoeb166) (tpx type vi) (liver tissue 2d-page spot 71b) (alu co-repressor 1) (sbbi10). [source:swissprot;acc:p30044]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2544\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6378.35\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6239.69\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02222\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peroxisomal 3,2-trans-enoyl-coa isomerase (ec 5.3.3.8) (dodecenoyl-coa delta-isomerase) (d3,d2-enoyl-coa isomerase) (dbi-related protein 1) (drs-1) (hepatocellular carcinoma-associated antigen 88). [source:swissprot;acc:o75521]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1726\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
7527.42\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7048.79\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0679\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
peroxisomal acyl-coa thioesterase 2b; likely ortholog of mouse peroxisomal acyl-coa thioesterase 2b. [source:refseq;acc:nm\_152331]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1987\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6175.69\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5829.74\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05934\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/